| URL | https://endpts.com/chinese-oncology-player-is-the- |
| Source | Endpoints News |
| Date Published | 05/24/2021 |
| Author Name | Josh Sullivan |
| Mentions specific company case(s) of reshoring, kept from offshoring, or transplant | Yes |
| Company/Division name | CARsgen Therapeutics |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Total number of jobs (added or to be added): | 200 |
| Year reshoring announced: | 2021 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 157 |
| Country(ies) from which reshored: | China |
| City reshored to: | Raleigh-Durham |
| State(s) reshored to: | NC |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | CAR-T cell therapies |